Pitolisant
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Prader-Willi Syndrome
Conditions
Prader-Willi Syndrome
Trial Timeline
Aug 20, 2025 → Aug 1, 2030
NCT ID
NCT07219485About Pitolisant
Pitolisant is a phase 3 stage product being developed by Harmony Biosciences for Prader-Willi Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07219485. Target conditions include Prader-Willi Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03433131 | Pre-clinical | Completed |
| NCT07219485 | Phase 3 | Recruiting |
| NCT05581576 | Approved | UNKNOWN |
| NCT05458128 | Phase 3 | Completed |
Competing Products
18 competing products in Prader-Willi Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Octreotide + Placebo | Novartis | Pre-clinical | 23 |
| Norditropin SimpleXx | Novo Nordisk | Pre-clinical | 22 |
| somatropin - GH naïve pediatric cohort + somatropin - GH treated cohort + somatropin - adult cohort | Pfizer | Phase 3 | 76 |
| Setmelanotide + Placebo | Rhythm Pharmaceuticals | Phase 2 | 49 |
| Setmelanotide | Rhythm Pharmaceuticals | Phase 2 | 49 |
| RGH-706 + Placebo | Richter Gedeon | Phase 2 | 49 |
| Carbetocin | Acadia Pharmaceuticals | Phase 3 | 72 |
| Carbetocin + Placebo | Acadia Pharmaceuticals | Phase 3 | 72 |
| DCCR | Soleno Therapeutics | Phase 3 | 72 |
| DCCR + DCCR + Placebo for DCCR | Soleno Therapeutics | Phase 3 | 72 |
| Pitolisant tablet | Harmony Biosciences | Phase 3 | 72 |
| Pitolisant oral tablets + Placebo oral tablet | Harmony Biosciences | Phase 2 | 47 |
| DCCR | Soleno Therapeutics | Phase 3 | 72 |
| VYKAT XR | Soleno Therapeutics | Pre-clinical | 18 |
| DCCR + Placebo for DCCR | Soleno Therapeutics | Phase 3 | 72 |
| NNZ-2591 | Neuren Pharmaceuticals | Phase 2 | 47 |
| BMB-101 + Placebo | Bright Minds Biosciences | Phase 2 | 47 |
| ARD-101 | Aardvark Therapeutics | Phase 2 | 44 |